<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04386980</url>
  </required_header>
  <id_info>
    <org_study_id>STI-RTX-3004</org_study_id>
    <nct_id>NCT04386980</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Resiniferatoxin in Patients With Knee Osteoarthritis Whose Total Knee Replacement Surgery is Delayed</brief_title>
  <official_title>A Phase 3, Randomized, Multi-center, Blinded, Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Resiniferatoxin Versus Placebo to Manage Pain in Patients With Osteoarthritis of the Knee Whose Total Knee Replacement Surgery is Delayed</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sorrento Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sorrento Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and safety study of resiniferatoxin versus placebo to manage pain in patients with&#xD;
      knee osteoarthritis whose TKR surgery is delayed&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study evaluates the efficacy and safety of intra-articular resiniferatoxin (RTX) versus&#xD;
      placebo to manage pain in patients with osteoarthritis of the knee whose Total Knee&#xD;
      Replacement surgery is delayed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    To be replaced by a different protocol&#xD;
  </why_stopped>
  <start_date type="Anticipated">April 2021</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in WOMAC pain and function subscales combined score</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) 3.1 numerical rating scale (NRS) [0-10 scale] Pain and Function combined score. The combined score ranges from 0 to 220; a higher score indicates greater severity of disease.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety of RTX: Incidence and severity of adverse events</measure>
    <time_frame>Baseline through Week 12</time_frame>
    <description>Incidence and severity of adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in analgesic usage</measure>
    <time_frame>Baseline to Week 4, Week 8, Week 12</time_frame>
    <description>Change in analgesic medication usage as reported by subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in WOMAC pain and function subscales combined score</measure>
    <time_frame>Baseline to Week 4, Week 8</time_frame>
    <description>Change in the WOMAC 3.1 NRS [0-10 scale] Pain and Function combined score. The combined score ranges from 0 to 220; a higher score indicates greater severity of disease.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Impression of Change (PGIC) in index knee pain</measure>
    <time_frame>Baseline to Week 4, Week 8, Week 12</time_frame>
    <description>Rating of change in index knee pain using the 7-point PGIC scale where 1 = very much improved and 7 = very much worsened.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <condition>Osteo Arthritis Knee</condition>
  <condition>Knee Pain Chronic</condition>
  <arm_group>
    <arm_group_label>Resiniferatoxin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>12.5 ug of Resiniferatoxin in 5 mL volume administered once intra-articularly</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>5 mL of diluent in normal saline administered once intra-articularly</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Resiniferatoxin</intervention_name>
    <description>Resiniferatoxin is a compound purified from natural sources.</description>
    <arm_group_label>Resiniferatoxin</arm_group_label>
    <other_name>RTX</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Diluent in normal saline</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able to give informed consent and comply with the study&#xD;
&#xD;
          -  Diagnosis of osteoarthritis (OA) in the index knee&#xD;
&#xD;
          -  Combined WOMAC A (pain) and C (function) subscale score of ≥ 23 at screening, using&#xD;
             the WOMAC 5-point Likert scale&#xD;
&#xD;
          -  Eligible for total knee replacement (TKR) surgery but unable to schedule surgery or&#xD;
             undergo scheduled surgery&#xD;
&#xD;
          -  In good general health; American Society of Anesthesiologists (ASA) physical status&#xD;
             category ≤3&#xD;
&#xD;
          -  Willing to use contraception for at least 30 days after receiving the study drug&#xD;
&#xD;
          -  Able to understand and complete study-related forms and adequately communicate with&#xD;
             the Investigator and site staff&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing osteonecrosis, subchondral insufficiency fracture, or knee pain&#xD;
             attributable to disease other than OA which may confound the ability to assess&#xD;
             response to treatment&#xD;
&#xD;
          -  Concurrent medical or arthritic conditions that could interfere with evaluation of the&#xD;
             index knee joint including, metabolic diseases, gout/pseudogout, hemochromatosis,&#xD;
             acromegaly, fibromyalgia, rheumatoid arthritis, or other inflammatory arthropathies&#xD;
             affecting the knee joint&#xD;
&#xD;
          -  Participants with significant pain in the back or other joints (ex. hip pain) which&#xD;
             may confound discrimination of pain assessment in index knee, as judged by the&#xD;
             Investigator&#xD;
&#xD;
          -  Undergone arthroscopic surgery of the index knee within 6 months of study drug&#xD;
             administration, or open surgery to the index knee within 24 months of study drug&#xD;
             administration&#xD;
&#xD;
          -  Undergone replacement surgery of the index knee&#xD;
&#xD;
          -  Presence of surgical hardware or other foreign bodies in the index knee&#xD;
&#xD;
          -  Index knee injections with corticosteroids within 30 days, or hyaluronic acid within 3&#xD;
             months, or platelet-rich plasma within 6 months prior to study drug administration.&#xD;
&#xD;
          -  Concurrent use of opioids for indications other than knee pain&#xD;
&#xD;
          -  Arterial or venous thrombi (including stroke), myocardial infarction, hospital&#xD;
             admission for unstable angina, cardiac angioplasty, or stenting within 12 months prior&#xD;
             to Screening.&#xD;
&#xD;
          -  Sensory peripheral neuropathy in the distal aspect of the target limb that is of&#xD;
             moderate severity or higher at Screening&#xD;
&#xD;
          -  Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome-related&#xD;
             illness, acute or history of chronic hepatitis B or hepatitis C; positive tests for&#xD;
             HIV-1 or -2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies&#xD;
&#xD;
          -  Specified laboratory abnormalities within 1 week of study drug administration&#xD;
&#xD;
          -  History within the past 2 years of substance abuse, including alcohol&#xD;
&#xD;
          -  Allergy or hypersensitivity to chili peppers, capsaicin, resiniferatoxin,&#xD;
             acetaminophen, tramadol, radiographic contrast agents, or any of the agents to be used&#xD;
             for sedation, anesthesia or nerve block on the day of study drug administration&#xD;
&#xD;
          -  Female participants who are pregnant, planning on becoming pregnant within 30 days of&#xD;
             receiving study drug, or are breastfeeding at Screening&#xD;
&#xD;
          -  Any medical condition or medical comorbidities that, in the Investigator's opinion,&#xD;
             could adversely impact study participation or safety, conduct of the study, or&#xD;
             interfere with pain assessments&#xD;
&#xD;
          -  Participated in a clinical study of an investigational drug within 4 half-lives of&#xD;
             Screening or are scheduled to receive an investigational agent (therapy or device)&#xD;
             while participating in this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Monica Luchi, MD</last_name>
    <role>Study Director</role>
    <affiliation>Sorrento Therapeutics, Inc.</affiliation>
  </overall_official>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>May 8, 2020</study_first_submitted>
  <study_first_submitted_qc>May 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2020</study_first_posted>
  <last_update_submitted>November 2, 2021</last_update_submitted>
  <last_update_submitted_qc>November 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>osteoarthritis</keyword>
  <keyword>knee pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

